⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 1, 2024AME Clinical Trials ReviewOpen Access

ADAURA: redefining the role of target therapy in resectable lung adenocarcinoma

Jairo A. Zuluaga Leonardo Rojas Óscar Arrieta Andrés F. Cardona

View Full Paper

Ask AI

Bookmark

Share

Abstract

Keywords: Targeted therapy; lung adenocarcinoma (LUAD); epidermal growth factor receptor mutations (EGFRm); osimertinib

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zuluaga et al. (2024) studied this question.

synapsesocial.com/papers/68e713edb6db64358768d36c https://doi.org/10.21037/actr-23-17

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Role of EGFR-TKIs in Nonmetastatic Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Comprehensive ReviewHuman Clinical Trial · 2026 · 2 citations
2Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational studyCohort Study · 2026
3A new, potential and safe neoadjuvant therapy strategy in epidermal growth factor receptor mutation-positive resectable non-small-cell lung cancer-targeted therapy: a retrospective study2024 · 3 citations
4ERK/GATAD2A/SAA1 axis drives osimertinib resistance via NF-κB and macrophage reprogramming in EGFR-mutated lung adenocarcinomaOriginal Research · 2026
5Role of radiotherapy in the treatment of <i>EGFR</i> -mutant non-small-cell lung cancer: a narrative reviewLiterature Review · 2026

Abstract 1226: Genomically encoded lineage plasticity drives resistance to EGFR targeted therapy in lung adenocarcinoma2024
Recent advances in EGFR-targeted therapies for non-small cell lung cancer2026
The microRNA Expression Signature of Lung Adenocarcinoma Harboring EGFR Mutations: Identification of Therapeutic Targets for EGFR-TKI Combination Therapy2026
Immediate or deferred non-culprit lesion pci in myocardial infarction: refining the timing of completenessAME Clinical Trials Review · 2026

AMore from AME Clinical Trials Review